Interference of Anti-CD38 in Multiple Myeloma Patients

Background: Darzalex (Daratumumab), the first therapeutic CD38 monoclonal antibody to treat multiple myeloma, was approved by Health Canada in June 2016. The CD38 transmembrane protein is highly expressed in malignant myeloma cells. This human CD38-directed (IgG1) monoclonal antibody reacts with glycoprotein found on the surface of many types of cells including red blood cells. It binds to CD38 expressed on RBCs and may result in positive indirect antiglobulin tests (IAT) performed to identify clinically significant alloantibodies.
Source: Transfusion Medicine Reviews - Category: Hematology Authors: Source Type: research